Skip to main content

Table 2 Comparisons of parameters before and after 12-week treatment in type 2 diabetes

From: SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway

Variable

UACR<30 mg/g

30≤UACR ≤300 mg/g

UACR>300 mg/g

Pre-treatment

Post-treatment

p-value

Pre-treatment

Post-treatment

p-value

Pre-treatment

Post-treatment

p-value

BW (kg)

76.50±12.67

73.04±12.55

<0.001

72.33±16.07

69.50±15.39

<0.001

68.63±14.58

65.84±14.12

<0.001

WC (cm)

88±9

84±8

<0.001

91±11

87±10

<0.001

87±11

84±11

<0.001

HC (cm)

97±6

95±7

0.068

98±10

95±8

0.001

94±8

91±7

<0.001

HbA1c (%)

7.53±1.41

7.12±1.12

0.054

8.31±1.38

7.46±1.16

0.042

7.90±1.78

7.43±1.27

0.150

TC (mmol/L)

5.06 ±1.03

5.03±0.94

0.894

4.36±0.78

4.49±1.09

0.480

5.20±1.32

4.91±1.13

0.269

TG (mmol/L)

1.54 (1.08, 2.31)

1.35 (1.01, 2.05)

0.191

1.69 (1.20, 2.03)

1.41 (0.92, 1.93)

0.028

1.34 (1.17, 2.45)

1.62 (1.13, 2.64)

0.638

LDL-C (mmol/L)

3.21±0.73

3.33±0.74

0.476

2.67±0.59

2.85±0.82

0.118

3.34±0.86

3.21±0.84

0.433

HDL-C (mmol/L)

1.13±0.16

1.18±0.13

0.021

1.21±0.29

1.24±0.24

0.320

1.15±0.23

1.17±0.24

0.493

Scr (umol/L)

78±14

74±14

0.137

74±16

73±18

0.920

99±42

100±39

0.563

UA (umol/L)

358±100

327±86

0.048

347±101

367±103

0.481

395±87

372±70

0.156

eGFR (ml/min/1.73m2)

99±21

103±19

0.156

88±20

87±22

0.764

74±24

70±21

0.090

24-h proteinuria (mg/d)

88 (77, 111)

119 (81, 171)

0.079

183 (132, 226)

193 (127, 269)

0.983

970 (676, 2345)

821 (273, 1893)

0.006

UACR (mg/g)

6 (4, 12)

6 (4, 10)

0.848

87 (42, 203)

75 (21, 152)

0.003

861 (459, 1966)

738 (213, 1482)

0.037

SBP (mmHg)

128±14

123±14

0.148

135±17

130±15

0.146

138 ±17

134±15

0.126

DBP (mmHg)

79±12

77±12

0.258

79±11

73±10

0.018

78±9

76±11

0.506

ALD (pg/ml)

168 (120, 220)

182 (142, 255)

0.526

176 (128, 225)

197 (153, 277)

0.263

163 (121, 223)

168 (122, 240)

0.755

Ang II (pg/ml)

98 (83, 111)

96 (81, 138)

0.259

90 (86, 124)

97 (81, 174)

0.737

109 (88, 125)

107 (90, 194)

0.639

PRA (ng/ml/h)

1.38 (0.51, 2.86)

3.15 (1.20, 4.91)

0.211

0.86 (0.33, 2.59)

0.84 (0.25, 2.37)

0.926

0.68 (0.21, 2.50)

0.63 (0.24, 2.86)

0.614

8-OHdG (ng/mL)

4.50 (2.31, 10.39)

3.35 (0.89, 5.14)

0.106

8.00 (2.55, 9.38)

1.88 (0.50, 3.36)

0.001

11.18 (6.40, 13.42)

1.90 (0.55, 5.08)

<0.001

AGEs (ug/mL)

775 (376, 932)

115 (22, 257)

0.001

777 (147, 1160)

136 (19, 358)

0.003

755 (413, 933)

210 (49, 462)

0.001

  1. Data are expressed as mean±standard deviation or median (interquartile rang)
  2. Abbreviations UACR: urinary albumin/creatinine ratio; BW: body weight; WC: Waist Circumference; HC: Hip Circumference; HbA1c: Glycated hemoglobin; TC: Total choles-terol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; Scr: serum creatinine; UA: Uric acid; eGFR: estimated Glomerular Filtration Rate; 24-h proteinuria: 24-hour Proteinuria; SBP:Systolic blood pressure; DBP: Diatolic blood pressure; ALD: Aldosterone; Ang II: angiotensin II; PRA: plasma renin activity; 8-OHdG: 8-hydroxy-2- deoxyguanosine; AGEs: advanced glycation end products
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us